You are here

Align Technology Announces Second Quarter 2018 Financial Results

  • Q2 revenues up 37.5% year-over-year to a record $490.3 million, and diluted EPS of $1.30
  • Q2 operating income up 46.8% year-over-year to $122.7 million, operating margin of 25.0%
  • Q2 total Invisalign case shipments up 30.5% year-over-year to 302.7 thousand
  • Q2 Invisalign cases for teenage patients up 42.1% year-over-year to 78.4 thousand
  • Q2 iTero scanner and services revenues up 60.9% year-over-year to $57.0 million

SAN JOSE, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq:ALGN) today reported financial results for the second quarter ended June 30, 2018. Invisalign case shipments in the second quarter of 2018 (Q2’18) were 302.7 thousand, up 30.5% year-over-year. Americas and International region case shipments were up year-over-year 22.2% and 45.4%, respectively. Q2’18 Invisalign cases for teenage patients were 78.4 thousand, up 42.1% year-over-year. Q2’18 revenues were $490.3 million, up 37.5% year-over-year and Q2’18 operating income was $122.7 million, up 46.8% year-over-year resulting in an operating margin of 25.0%.  Net profit was $106.1 million, or $1.30 per diluted share, up $0.45 year-over-year.

Commenting on Align’s Q2 2018 results, Align Technology President and CEO Joe Hogan said, “I’m pleased to report another better than expected quarter for Align.  Our second quarter results reflect strong growth across our customer channels with record volume in all regions and in almost every country market. Year-over-year revenue growth of 37.5% was driven by continued momentum from Invisalign doctors and increased adoption of Invisalign treatment for teenage patients which grew 42.1%. Q2 Invisalign volume growth of 30.5% year-over-year reflects increased utilization and expansion of our customer base, which was over 50,000 for the first time and included more than 5,000 new Invisalign-trained doctors.  We also saw momentum from the iTero scanner and services business which includes the continued rollout of iTero scanners across Heartland Dental’s installed base, as well as the first iTero scanner shipments to China.”

GAAP Summary Financial Comparisons
Second Quarter Fiscal 2018

 Q2’18Q1’18Q2’17 Q/Q Change Y/Y Change
Invisalign Case Shipments1 302,685 272,235 231,890+11.2%+30.5%
Net Revenues$490.3M$436.9M$356.5M+12.2%+37.5%
Clear Aligner2$433.3M$385.5M$321.0M+12.4%+35.0%
Scanner & Services$57.0M$51.4M$35.4M+10.9%+60.9%
Net Profit$106.1M$95.9M$69.2M+10.7%+53.4%
Diluted EPS$1.30$1.17$0.85+$0.13+$0.45

Note: Changes and percentages are based on actual values and may affect totals due to rounding
1 Invisalign shipment figures do not include SmileDirectClub aligners
2 Clear aligner revenue includes revenues from Invisalign clear aligners and SmileDirectClub aligners

As of June 30, 2018, Align had $720.7 million in cash, cash equivalents and marketable securities compared to $673.0 million as of March 31, 2018. In May 2018, we announced an additional $600 million stock buy-back authorization.  We also have $100 million remaining under the April 2016 repurchase program, which we expect to utilize during the remainder of 2018. 
Announcements and Highlights

  • Today, Align issued a separate press release announcing that the Company has opened new facilities in Costa Rica to support continued long term growth.  The Company hosted a grand opening celebration on Friday, July 20 attended by Costa Rican President Carlos Alvarado Quesada and local government officials. Today, the Company also announced that it has received Certificate of Medical Device Registration and Certificate of Production from the China Food and Drug Administration (CFDA) to manufacture the iTero Element intraoral scanner in China. Align had previously announced in April that it had received approval from the CFDA to market the iTero Element intraoral scanner in China.

Q2 2018 Company Highlights. During the second quarter Align announced the following:

  • The One Millionth Invisalign case for the Europe, Middle East and Africa (“EMEA”) region.  This is a significant milestone for the Company with more than 34 thousand Invisalign-trained orthodontists and general dentists in the region and reflects accelerating adoption of Invisalign clear aligner therapy in EMEA.

  • Eleven recipients of research grants under the Company’s Annual Research Award Program. Now in its ninth year of funding, nearly $300,000 has been awarded for 2018 to researchers at universities in the Americas, Europe, and Asia Pacific regions.

  • The grand opening of the first Invisalign treatment planning facility in Europe, located in Cologne, Germany. The Cologne facility is one of only three Invisalign treatment planning facilities in the world and reflects the rapid growth and expansion of Align globally. It serves as a training facility for Invisalign doctors within the German-speaking market, providing clinical education and support in local language for doctors in Germany, Austria, Switzerland and Lichtenstein.

  • The extension of the Invisalign product family with Invisalign First clear aligners, designed with features specifically for younger patients with early mixed dentition (mixture of primary/baby and permanent teeth). Phase 1 treatment is early interceptive orthodontic treatment for young patients, traditionally done through arch expanders, or partial metal braces, before all permanent teeth have erupted - typically at ages 6 through 10 years. Invisalign First clear aligners are designed specifically to address a broad range of younger patients' malocclusions, including shorter clinical crowns, management of erupting dentition, and predictable dental arch expansion.

  • A new expanded Invisalign product portfolio that includes new options and greater flexibility to treat a broader range of patients.  The new Invisalign product portfolio offers doctors more choices by extending desirable features across the entire portfolio and creating new Invisalign Treatment Packages, as well as new options to treat young patients with early mixed dentition. The new end-to-end Invisalign portfolio now includes clear aligner product offerings for almost every patient age group and case complexity to make it easier for doctors to tailor treatment planning to the needs of each unique patient.

  • The new Invisalign Go product with a more user-friendly iTero digital chairside experience and greater flexibility to treat a wider range of mild to moderate cases such as crowded or gap teeth that require teeth straightening prior to restorative treatments.  Invisalign Go also incorporates new data-driven clinical protocols for predictable tooth movement and automated case assessments that leverage over 5.5 million Invisalign patients treated to date. These improvements make it easier for dentists to tailor their treatment plans to the individual needs of each patient.

  • The commercial availability of Vivera Retainers with Precision Bite Ramps, the first retainers in the market that can be customized to provide additional support after deep bite correction. First introduced in 2014 with Invisalign G5 Innovations, Precision Bite Ramps are designed to disocclude the posterior teeth or "open the bite" for improved efficiency in deep bite Invisalign treatments.

  • The expansion of the iTero Element portfolio with the launch of the iTero Element 2 and the iTero Element Flex scanners. These additions build on the existing high precision, full-color imaging and fast scan times of the iTero Element portfolio. The next-generation iTero Element 2 is designed for greater performance with 2X faster start-up and 25% faster scan processing time compared to the iTero Element.

  • Regulatory approval from the China Food and Drug Administration (CFDA) to market the iTero Element intraoral scanner in China.

Q3 2018 Business Outlook

For the third quarter of 2018 (Q3’18), Align provides the following guidance:

  • Net revenues in the range of $493 million to $503 million, up approximately 28% to 31% over the same period a year ago
  • Invisalign case shipments in the range of 302 thousand to 307 thousand, up approximately 28% to 30% over the same period a year ago
  • Operating margin in the range of 24.2% to 24.9%
  • Diluted EPS in the range of $1.13 to $1.18

Align Web Cast and Conference Call

Align will host a conference call today, July 25, 2018 at 4:30 p.m. ET, 1:30 p.m. PT, to review its second quarter 2018 results, discuss future operating trends and the business outlook. The conference call will also be web cast live via the Internet.  To access the webcast, go to the “Events & Presentations” section under Company Information on Align’s Investor Relations web site at  To access the conference call, please dial 201-689-8261. An archived audio web cast will be available beginning approximately one hour after the call's conclusion and will remain available for approximately 12 months. Additionally, a telephonic replay of the call can be accessed by dialing 877-660-6853 with conference number 13681104 followed by #. For international callers, please dial 201-612-7415 and use the same conference number referenced above. The telephonic replay will be available through 5:30 p.m. ET on August 8, 2018.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, and iTero® intraoral scanners and services. Align’s products help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients. Visit for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit For additional information about iTero digital scanning system, please visit

Forward-Looking Statement

This news release, including the tables below, contains forward-looking statements, including statements regarding certain business metrics for the third quarter of 2018, including, but not limited to, anticipated net revenues, gross margin, operating expenses, operating profit, diluted earnings per share, tax rate including the financial impact of recent U.S. Tax Cuts and Jobs Act and case shipments.  Forward-looking statements contained in this news release and the tables below relating to expectations about future events or results are based upon information available to Align as of the date hereof. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. As a result, actual results may differ materially and adversely from those expressed in any forward-looking statement. Factors that might cause such a difference include, but are not limited to, difficulties predicting customer and consumer purchasing behavior, Align's ability to protect its intellectual property rights, continued compliance with regulatory requirements, competition from existing and new competitors, the willingness and ability of our customers to maintain and/or increase product utilization in sufficient numbers, the possibility that the development and release of new products does not proceed in accordance with the anticipated timeline, the possibility that the market for the sale of these new products may not develop as expected, or that the expected benefits of new or existing business relationships will not be achieved as anticipated, risks relating to international sales, which are increasingly a larger portion of our total revenues, the risks relating to Align's ability to sustain or increase profitability or revenue growth in future periods while controlling expenses, growth related risks, including capacity constraints and pressure on our internal systems and personnel, the security of customer and/or patient data is compromised for any reason, continued customer demand for our existing and new products, changes in consumer spending habits as a result of, among other things, prevailing economic conditions, levels of employment, salaries and wages and consumer confidence, the timing of case submissions from our doctors within a quarter, acceptance of our products by consumers and dental professionals, changes to our interpretation of the U.S. Tax Cuts and Jobs Act which may change as we receive additional clarification and implementation guidance, possibly materially, foreign operational, political and other risks relating to Align's international manufacturing operations, litigation risks, uncertainties involved in any contract dispute resolution and the possibility of Align choosing to settle the litigation for business or other reasons.  Align's ability to develop and successfully introduce new products and product enhancements and the loss of key personnel. These and other risks are detailed from time to time in Align's periodic reports filed with the Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 28, 2018. Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

(in thousands, except per share data)     
  Three Months Ended
June 30,
 Six Months Ended
June 30,
  2018 2017 2018 2017 
Net revenues $490,259  $356,482 $927,183  $666,823 
Cost of net revenues  124,677   85,565  234,193   160,281 
Gross profit  365,582   270,917  692,990   506,542 
Operating expenses:         
Selling, general and administrative  212,087   162,964  411,712   314,112 
Research and development  30,804   24,384  60,395   47,188 
Total operating expenses  242,891   187,348  472,107   361,300 
Income from operations  122,691   83,569  220,883   145,242 
Interest income  1,917   1,441  4,093   2,636 
Other income (expense), net  (7,099)  1,771  (6,922)  2,221 
Net income before provision for income taxes and equity in losses of investee  117,509   86,781  218,054   150,099 
Provision for income taxes  7,703   15,387  10,605   8,164 
Equity in losses of investee, net of tax  3,701   2,215  5,478   3,336 
Net income $106,105  $69,179 $201,971  $138,599 
Net income per share:         
Basic $1.32  $0.86 $2.52  $1.73 
Diluted $1.30  $0.85 $2.48  $1.70 
Shares used in computing net income per share:         
Basic  80,216   80,188  80,127   80,047 
Diluted  81,471   81,631  81,575   81,668 
* During Q1'18, we adopted the ASC 606, "Revenues from Contracts with Customers" using the full retrospective method. The adoption of ASC 606 did not have a material impact on our Condensed Consolidated Statements of Operations presented herein.


(in thousands) 
  June 30,
 December 31,
Current assets:     
Cash and cash equivalents $547,993 $449,511 
Marketable securities, short-term  164,629  272,031 
Accounts receivable, net  374,371  324,189 
Inventories  47,252  31,688 
Prepaid expenses and other current assets  126,754  80,948 
Total current assets  1,260,999  1,158,367 
Marketable securities, long-term  8,061  39,948 
Property, plant and equipment, net  447,933  348,793 
Equity method investments  49,128  54,606 
Goodwill and intangible assets, net  85,307  89,068 
Deferred tax assets  45,859  49,334 
Other assets  19,302  43,893 
Total assets $1,916,589 $1,784,009 
Current liabilities:     
Accounts payable $48,744 $36,776 
Accrued liabilities  196,754  195,562 
Deferred revenues  321,148  267,713 
Total current liabilities  566,646  500,051 
Income tax payable  115,701  114,091 
Other long-term liabilities  15,283  15,579 
Total liabilities  697,630  629,721 
Total stockholders' equity  1,218,959  1,154,288 
Total liabilities and stockholders' equity $1,916,589 $1,784,009 
* During Q1'18, we adopted the ASC 606, "Revenues from Contracts with Customers" using the full retrospective method. Condensed Consolidated Balance Sheet as of December 31,2017 has been recasted to comply with the adoption.


(in thousands) 
  Six Months Ended
June 30,
Net income $201,971  $138,599  
Net cash provided by operating activities  217,121   158,088  
Net cash provided by (used in) investing activities  54,003   (111,718) 
Net cash used in financing activities  (170,745)  (84,240) 
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash  (1,923)  3,640  
Net increase (decrease) in cash, cash equivalents, and restricted cash  98,456   (34,230) 
Cash, cash equivalents, and restricted cash at beginning of the period  450,125   393,019  
Cash, cash equivalents, and restricted cash at end of the period $548,581  $358,789  
*During Q1'18, we adopted ASU 2016-18, "Statement of Cash Flows - Restricted Cash" on a retrospective basis. Condensed Consolidated Statement of Cash Flows for the six months ended June 30, 2017 has been recasted to comply with the adoption.


    Q1 Q2 Q3 Q4 Fiscal Q1 Q2  
Invisalign Average Selling Price (ASP):                 
 Worldwide ASP  $1,270  $1,285  $1,310  $1,305  $1,295  $1,310  $1,315   
 International ASP  $1,345  $1,340  $1,395  $1,400  $1,375  $1,435  $1,425   
Invisalign Cases Shipped by Geography:                 
 Americas   134,450   148,470   147,660   155,625   586,205   166,665   181,425   
 International   73,610   83,420   88,405   99,405   344,840   105,570   121,260   
 Total Cases Shipped   208,060   231,890   236,065   255,030   931,045   272,235   302,685   
 YoY % growth   27.1%  31.0%  32.8%  34.2%  31.4%  30.8%  30.5%  
 QoQ % growth   9.5%  11.5%  1.8%  8.0%    6.7%  11.2%  
Number of Invisalign Doctors Cases Were Shipped To:                
 Americas   24,595   25,570   25,865   26,480   38,230   27,105   28,280   
 International   14,270   15,695   16,740   18,505   26,175   19,700   21,805   
 Total Doctors Cases Shipped To   38,865   41,265   42,605   44,985   64,405   46,805   50,085   
Invisalign Doctor Utilization Rates**:                 
 North America   5.6   5.9   5.8   6.0   15.8   6.3   6.6   
 North American Orthodontists   12.6   13.6   13.8   14.0   46.6   15.3   16.4   
 North American GP Dentists   3.1   3.3   3.1   3.3   8.2   3.4   3.6   
 International   5.2   5.3   5.3   5.4   13.2   5.4   5.6   
 Total Utilization Rates   5.4   5.6   5.5   5.7   14.5   5.8   6.0   
Number of Invisalign Doctors Trained:                 
 Americas   1,040   1,820   1,740   1,685   6,285   1,605   1,795   
 International   2,220   3,055   2,540   2,400   10,215   2,645   3,300   
 Total Doctors Trained Worldwide   3,260   4,875   4,280   4,085   16,500   4,250   5,095   
 Total to Date Worldwide   118,730   123,605   127,885   131,970   131,970   136,220   141,315   
Note: Historical public data may differ due to rounding. Additionally, rounding may effect totals. Effective Q1'18, Americas region includes North America and LATAM. International region includes EMEA and APAC. We have recasted historical data to reflect the change.
* Invisalign business metrics exclude SmileDirectClub aligners. 
** # of cases shipped / # of doctors to whom cases were shipped. LATAM utilization rate is not separately disclosed, but included in the total utilization rates. 
(in thousands)
    Q1 Q2 Q3 Q4 Fiscal Q1 Q2  
Stock-based Compensation (SBC)                 
 SBC included in Gross Profit  $925  $768  $833  $804  $3,330  $881  $900   
 SBC included in Operating Expenses   13,887   13,477   14,134   14,026   55,524   14,949   15,990   
 Total SBC Expense  $14,812  $14,245  $14,967  $14,830  $58,854  $15,830  $16,890   

The outlook figures provided below and elsewhere in this press release are approximate in nature since Align’s business outlook is difficult to predict.  Align’s future performance involves numerous risks and uncertainties and the company’s results could differ materially from the outlook provided.  Some of the factors that could affect Align’s future financial performance and business outlook are set forth under “Forward Looking Information” above in this press release. 
Financial Outlook          
(in millions, except per share amounts and percentages)        
  Q3'18 Guidance        
Net Revenues $493 - $503        
Gross Margin 74.0% - 74.4%        
Operating Expenses $245 - $249        
Operating Margin 24.2% - 24.9%        
Net Income per Diluted Share $1.13 - $1.18(1, 2)       
Business Metrics: Q3'18        
Case Shipments 302K - 307K        
Capital Expenditure $60M - $65M        
Depreciation & Amortization $10M - $11M        
Diluted Shares Outstanding 81.6M(2)       
Stock Based Compensation Expense $18.8M        
Effective Tax Rate ~21%(1)       
(1) Includes excess tax benefits related to share-based compensation expense pursuant to ASU 2016-09 
(2) Excludes any stock repurchases during the quarter 

Align Technology
Madelyn Homick
(408) 470-1180

Ethos Communication
Shannon Mangum Henderson
(678) 261-7803

Wednesday, July 25, 2018 - 16:00